Business
Crescita Therapeutics Inc.(TM) and Tetra Natural Health Collaborate to Enhance Transdermal Delivery of Beta-Caryophyllene in Tetra's Dermatology Product Portfolio
Crescita Therapeutics Inc.™ and Tetra Natural Health Collaborate to Enhance Transde...
About this update from Crescita Therapeutics, Inc.
[{"type":"text","content":"\n\n\n\nCrescita Therapeutics Inc.™ and Tetra Natural Health Collaborate to Enhance Transdermal Delivery of Beta-Caryophyllene in Tetra's Dermatology Product Portfolio\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nLAVAL, QC, and ORLEANS, ON, Feb. 4, 2019\n\n\n\nLAVAL, QC, and ORLEANS, ON, Feb. 4, 2019 /CNW/ - Crescita Therapeutics Inc. (\"Crescita\") (TSX: CTX), a Canadian commercial dermatology company and Tetra Natural Health (NHP), a subsidiary of Tetra Bio-Pharma, a leader in cannabinoid-derived drug discovery and development, (\"Tetra\") (TSX-V: TBP) (OTCQB: TBPMF) today announced an agreement to develop an enhanced version of Tetra's dermatology portfolio using Crescita's patented transdermal delivery technologies: Multiplexed Molecular Penetration Enhancer (\"MMPE™\") and DuraPeel™. The primary active ingredient contained in the product portfolio to be reformulated is beta-caryophyllene (\"Beta-C\"), which is known to work on Cannabidiol (\"CBD\") 2 receptors. The testing methodology and the clinical development made possible by the collaboration will help optimize the delivery of Beta-C and several other active ingredients into the skin and local tissues.\n\n \n \n\n \nSome of Tetra's dermatology products have already been approved by Health Canada as natural health products, and address several medical conditions, including but not limited to, muscle and joint pain, cold sores and hemorrhoids. In late 2018, Crescita published the favorable results of a study demonstrating the enhanced permeation of CBD, the non-psychoactive component of cannabis. The in-vitro skin permeation study showed that both MMPE and DuraPeel significantly increased the transdermal permeation of CBD over the control formulation by up to 14- and 6-fold, respectively. Based on these results, Tetra believes that the use of Crescita's patented technologies will improve the permeability and potentially, the efficacy of Beta-C and will enhance the intellectual property of its dermatology portfolio. \nIn addition, the companies have entered into...